[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][O][C][=Branch1][C][=O][C][=C][Branch2][Ring1][N][N][C][=Branch2][Ring1][=Branch1][=C][Branch1][=N][C@@H1][Ring1][=Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1][Cl][C][=Branch1][C][=O][O][C][C][C][O][C][C][N]"}, {"from": "gpt", "value": "The molecule is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.  Levamlodipine was granted FDA approval on 19 December 2019."}]